-
Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach
-
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
-
Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer
-
Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
-
Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study
-
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
-
Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide
-
Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms
-
Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
-
Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics
-
Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors
-
The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease
-
Target adverse event profiles for predictive safety in the postmarket setting
-
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development
